Brief report | Open | Open Peer Review | Published:
Metallothionein genes: no association with Crohn's disease in a New Zealand population
Journal of Negative Results in BioMedicinevolume 11, Article number: 8 (2012)
Metallothioneins (MTs) are excellent candidate genes for Inflammatory Bowel Disease (IBD) and have previously been shown to have altered expression in both animal and human studies of IBD. This is the first study to examine genetic variants within the MT genes and aims to determine whether such genetic variants have an important role in this disease. 28 tag SNPs in genes MT1 (subtypes A, B, E, F, G, H, M, X), MT2, MT3 and MT4 were selected for genotyping in a well-characterized New Zealand dataset consisting of 406 patients with Crohn's Disease and 638 controls. We did not find any evidence of association for MT genetic variation with CD. The lack of association indicates that genetic variants in the MT genes do not play a significant role in predisposing to CD in the New Zealand population.
Inflammatory bowel disease (IBD) is a disorder characterised by chronic, relapsing inflammation of the gastrointestinal tract and is characterized by the presence of an increased level of reactive oxygen species in the mucosal intestinal tissue as well as oxidative DNA and protein damage, defective host-microbe interactions, immune cell infiltration, and disturbed T cell apoptosis. Metallothioneins (MTs) are able to affect all of these processes, making them good candidates for IBD. MTs are ubiquitous metal-binding proteins that have been highly conserved throughout evolution and are rapidly upregulated in response to an inflammatory stimulus. There are four main isoforms expressed in humans: MT1 (subtypes A, B, E, F, G, H, M, X), MT2, MT3 and MT4. These genes cluster together on a single locus on chromosome 16 (16q13) .
Support for the hypothesis of MTs playing an important role in the pathogenesis of IBD has come from various reports demonstrating altered MT expression in IBD. However these reports have been contradictory (for a summary see Waeytens et al., 2009 ) with some studies reporting MT upregulation in IBD [3, 4] and others demonstrating a downregulation [5–11]. The inconsistencies between the various studies may be explained by differences in patients samples such as age, medication, disease activity, zinc status, as well as from where the tissue was sampled (ileum or colon).
Whilst there have been several studies investigating expression of MTs in IBD, there have been no studies published to date investigating genetic variants in MTs and IBD. The aim of this study is to identify SNPs across these genes and to genotype these in a well-characterised Caucasian New Zealand IBD dataset and to examine the results for evidence of genetic association between any of the MT genes and IBD.
A total of 1044 subjects from New Zealand were included in the study: 406 CD patients and 638 age and sex matched controls. All participants self-reported European ancestry.
Clinical records were analysed to confirm diagnosis, and IBD status was defined using standard diagnostic criteria . Cases were phenotyped according to the Montreal Classification systems. Clinical characteristics of the CD patients are shown in table 1.
Participants consented to collection of peripheral blood or a buccal swab for DNA extraction and genotyping, and DNA was extracted from the blood/buccal samples using Qiagen's DNA extraction kit and following the manufacturer's instructions.
The study was conducted under ethical protocol MEC/04/12/011, authorised through the New Zealand Multi-Region Human Ethics Committee. All study subjects gave informed consent.
Tag SNPs in genes MT1 (subtypes A, B, E, F, G, H, M, X), MT2, MT3 and MT4 were selected using Hapmap release 28, and the tagger functionality within Haploview with pairwise tagging to identify SNPs using an r2 > 0.8 and a minor allele frequency > 5%. As a result 28 tag SNPs were selected for genotyping.
Genotyping was performed with the MassARRAY and iPlex systems of the Sequenom genotyping platform (Sequenom, San Diego, CA), which uses the MALDI-TOF primer extension assay [13, 14], according to manufacturers' recommendations.
Assays were optimized in 24 samples consisting of 20 reference Centre d'Etude du Polymorphisme Humain (CEPH) samples and 4 blanks.
All sample plates contained cases, controls, blanks, CEPH and duplicate samples. Quality control measures included independent double genotyping and, where available, comparison of our CEPH genotypes to those in the Hapmap database http://www.hapmap.org.
SNPs were tested for deviation from HWE in both cases and controls using a chi-square goodness-of-fit test. To determine if there were differences between cases and controls, genotype and allele frequencies for each SNP were analyzed by 2 × 3 and 2 × 2 Chi-square tables respectively
Genotype and phenotype associations were assessed by comparing allele frequencies between controls and patient subgroups defined using the clinical characteristics. These analyses were carried out using R (R: A language and environment for statistical computing, R Foundation for Statistical Computing, Vienna, Austria. ISBN 3-900051-07-0, URL http://www.R-project.org/) and SAS (V9.1 SAS Institute., Cary, NC, USA).
To determine linkage disequilibrium (LD) between SNPs and to define haplotype blocks, we uploaded our data into Haploview . Haplotype blocks were defined using the default algorithm which uses confidence intervals . Haplotype analysis was carried using HAPLO.SCORE in R to test for association of these haplotypes with CD.
For all analyses we considered a p values less than 0.05 to indicate statistical significance.
Results and discussion
Three SNPs did not fit into the Sequenom multiplexes: rs1827210 (MT1M), rs11076161 (MT1A), rs2298846 (MT1G). Two SNPs failed to be successfully genotyped: rs1827208 (MT1M) and rs12448654 (MT1G). One SNP was out of HWE in the control samples and so was excluded from further analysis: rs12051311 (MT1B). Thus there were 22 SNPs with genotype data for analysis. Genotype and allele counts/frequencies and p-values are shown in table 2. One SNP rs4784708 (MT1H) was found to be associated with CD (genotypic p = 0.0197, allelic p = 0.016) but after applying multiple testing correction using FDR the result is no longer statistically significant. Thus we can conclude that individual SNPs in the MT genes are not associated with CD.
Calculations of statistical power using PS 2.1.31  show that using our case-control sample set although we have good power to detect an odds ratio of 1.3 for common SNPs (for example for a SNP with MAF 0.42 (e.g., rs11644094) we have 86.5% power) the power is considerably lower for SNPs with low MAF. For example for a SNP with MAF of 0.02 (e.g., rs9936741) we have 16.1% power. Thus, an association of metallothionein genes with CD cannot be entirely ruled out as it may simply be that we do not have the power in our study to detect such an association. A replication study in a larger sample set is encouraged.
There are 5 haplotype blocks in this region (Figure 1) but examining the different haplotypes we did not find any associations with CD (data not shown but available on request).
We also undertook a phenotype analysis and after multiple testing corrections none of the SNPs were associated with any of the different clinical characteristics of CD (data not shown but available on request).
This is the first study to investigate genetic association with MT SNPs and IBD. In summary although MT genes are good candidates for CD, the present study failed to detect any significant associations. The lack of association indicates that genetic variants in the MT genes do not play a significant role in predisposing to CD in the New Zealand population.
Karin M, Eddy RL, Henry WM, Haley LL, Byers MG, Shows TB: Human metallothionein genes are clustered on chromosome 16. Proceedings of the National Academy of Sciences of the United States of America. 1984, 81 (17): 5494-5498. 10.1073/pnas.81.17.5494.
Waeytens A, De Vos M, Laukens D: Evidence for a potential role of metallothioneins in inflammatory bowel diseases. Mediators Inflamm. 2009, 729172-
Bruwer M, Schmid KW, Metz KA: Increased expression of metallothionein in inflammatory bowel disease. Inflammation Research. 2001, 50 (60): 289-293.
Dooley TP, Curto EV, Reddy SP: Regulation of gene expression in inflammatory bowel disease and correlation with IBD drugs: screening by DNA microarrays. Inflammatory Bowel Diseases. 2004, 10 (1): 1-14. 10.1097/00054725-200401000-00001.
Clarkson JP, Elmes ME, Jasani B, Webb M: Histological demonstration of immunoreactive zinc metallothionein in liver and ileum of rat and man. Histochem J. 1985, 17 (3): 343-352. 10.1007/BF01004596.
Elmes ME, Clarkson JP, Jasani B: Histological demonstration of immunoreactive metallothionein in rat and human tissues. Experientia Suppl. 1987, 52: 533-537.
Mulder TP, Verspaget HW, Janssens AR: Decrease in two intestinal copper/zinc containing proteins with antioxidant function in inflammatory bowel disease. Gut. 1991, 32 (10): 1146-1150. 10.1136/gut.32.10.1146.
Sturniolo GC, Mestriner C, Lecis PE: Altered plasma and mucosal concentrations of trace elements and antioxidants in active ulcerative colitis. Scand J Gastroenterol. 1998, 33 (6): 644-649. 10.1080/00365529850171936.
Lawrance IC, Fiocchi C, Chakravarti S: Ulcerative colitis and Crohn's disease: distinctive gene expression profiles and novel susceptibility candidate genes. Hum Mol Genet. 2001, 10 (5): 445-456. 10.1093/hmg/10.5.445.
Ioachim E, Michael M, Katsanos C: The immunohistochemical expression of metallothionein in inflammatory bowel disease. Correlation with HLA-DR antigen expression, lymphocyte subpopulations and proliferation-associated indices. Histol Histopathol. 2003, 18 (1): 75-82.
Kruidenier L, Kuiper I, Van Duijn W: Imbalanced secondary mucosal antioxidant response in inflammatory bowel disease. J Pathol. 2003, 201 (1): 17-27. 10.1002/path.1408.
Lennard-Jones JE: Classification of inflammatory bowel disease. Scandinavian Journal of Gastroenterology. 1989, 170: 2-6.
Jurinke C, van der Boom D, Cantor CR, Köster H: The use of massARRAY technology for high throughput genotyping. Adv Biochem Eng Biotechnol. 2002, 77: 57-74.
Storm N, Darnhofer-Patel B, van der Boom D, Rodi CP: MALDI-TOF mass spectrometry-based SNP genotyping. Methods Molecular Biology. 2003, 212: 241-262.
Barrett JC, Fry B, Maller J, Daly MJ: Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics. 2005, 21 (2): 263-265. 10.1093/bioinformatics/bth457.
Gabriel SB, Schaffner SF, Nguyen H: The structure of haplotype blocks in the human genome. Science. 2002, 296 (5576): 2225-2229. 10.1126/science.1069424.
Bender R, Lange S: Adjusting for multiple testing--when and how?. Journal of Clinical Epidemiology. 2001, 54: 343-349. 10.1016/S0895-4356(00)00314-0.
Jones HE, Ohlssen DI, Spiegelhalter DJ: Use of the false discovery rate when comparing multiple health care providers. Journal of Clinical Epidemiology. 2008, 61: 232-240. 10.1016/j.jclinepi.2007.04.017.
Dupont WD, Plummer WD: Power and Sample Size Calculations for Studies Involving Linear Regression. Controlled Clinical Trials. 1998, 19: 589-601. 10.1016/S0197-2456(98)00037-3.
We would like to thank the many patients with IBD who participated in this study, and also the control subjects.
We thank Wen-Jiun Lam for assistance with DNA extraction and preparation.
Nutrigenomics New Zealand is collaboration between AgResearch Ltd., Plant & Food Research and The University of Auckland with funding through the Ministry of Science and Innovation (MSI).
The authors declare that they have no competing interests.
ARM designed the study, performed the genotyping and QC, analysis and interpretation of data. She was primary author of the manuscript. AGF participated in participant recruitment and collection of clinical information from the patients. LRF was responsible for obtaining funding. All authors read and approved the final manuscript.